Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.[ Read More ]
The intrinsic value of one GILD stock under the base case scenario is HIDDEN Compared to the current market price of 88.4 USD, Gilead Sciences, Inc. is HIDDEN
Current Assets | 16.1 B |
Cash & Short-Term Investments | 7.26 B |
Receivables | 4.66 B |
Other Current Assets | 4.16 B |
Non-Current Assets | 46 B |
Long-Term Investments | 1.16 B |
PP&E | 5.32 B |
Other Non-Current Assets | 39.6 B |
Current Liabilities | 11.3 B |
Accounts Payable | 550 M |
Short-Term Debt | 1.8 B |
Other Current Liabilities | 8.93 B |
Non-Current Liabilities | 28.1 B |
Long-Term Debt | 23.2 B |
Other Non-Current Liabilities | 4.91 B |
Revenue | 27.1 B |
Cost Of Revenue | 5.97 B |
Gross Profit | 21.1 B |
Operating Expenses | 13 B |
Operating Income | 7.6 B |
Other Expenses | 1.99 B |
Net Income | 5.61 B |
Net Income | 5.61 B |
Depreciation & Amortization | 2.69 B |
Capital Expenditures | -585 M |
Stock-Based Compensation | 795 M |
Change in Working Capital | -2.3 B |
Others | 899 M |
Free Cash Flow | 7.42 B |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
1 week ago
Nov 06, 2024
|
Sell 456 K USD
|
Mercier Johanna
Chief Commercial Officer |
- 5000
|
91.28 USD |
1 week ago
Nov 06, 2024
|
Sell 1.88 M USD
|
Parsey Merdad
Chief Medical Officer |
- 20590
|
91.5 USD |
1 week ago
Nov 06, 2024
|
Sell 458 K USD
|
Parsey Merdad
Chief Medical Officer |
- 5000
|
91.5 USD |
1 month ago
Oct 01, 2024
|
Sell 168 K USD
|
Parsey Merdad
Chief Medical Officer |
- 2000
|
83.83 USD |
2 months ago
Sep 12, 2024
|
Sell 1.8 M USD
|
Parsey Merdad
Chief Medical Officer |
- 21246
|
84.5 USD |
2 months ago
Sep 12, 2024
|
Sell 1.34 M USD
|
Mercier Johanna
Chief Commercial Officer |
- 15925
|
84.23 USD |
2 months ago
Sep 12, 2024
|
Sell 1.12 M USD
|
Mercier Johanna
Chief Commercial Officer |
- 13432
|
83.25 USD |
2 months ago
Aug 28, 2024
|
Sell 742 K USD
|
Mercier Johanna
Chief Commercial Officer |
- 9513
|
78.03 USD |
3 months ago
Aug 13, 2024
|
Sell 406 K USD
|
Mercier Johanna
Chief Commercial Officer |
- 5490
|
73.98 USD |
4 months ago
Jul 01, 2024
|
Sell 137 K USD
|
Parsey Merdad
Chief Medical Officer |
- 2000
|
68.63 USD |
7 months ago
Apr 01, 2024
|
Sell 146 K USD
|
Parsey Merdad
Chief Medical Officer |
- 2000
|
72.96 USD |
8 months ago
Feb 28, 2024
|
Sell 146 K USD
|
Parsey Merdad
Chief Medical Officer |
- 2000
|
73.18 USD |
8 months ago
Feb 29, 2024
|
Sell 599 K USD
|
Parsey Merdad
Chief Medical Officer |
- 8230
|
72.7368 USD |
10 months ago
Jan 16, 2024
|
Sell 429 K USD
|
Dickinson Andrew D
Chief Financial Officer |
- 5000
|
85.78 USD |
10 months ago
Jan 09, 2024
|
Sell 702 K USD
|
Mercier Johanna
Chief Commercial Officer |
- 8242
|
85.23 USD |
1 year ago
Oct 17, 2023
|
Sell 400 K USD
|
Dickinson Andrew D
Chief Financial Officer |
- 5000
|
80.0034 USD |
1 year ago
Sep 12, 2023
|
Sell 116 K USD
|
Parsey Merdad
Chief Medical Officer |
- 1501
|
76.99 USD |
1 year ago
Jul 20, 2023
|
Sell 400 K USD
|
Dickinson Andrew D
Chief Financial Officer |
- 5000
|
80 USD |
1 year ago
Jun 13, 2023
|
Sell 114 K USD
|
Parsey Merdad
Chief Medical Officer |
- 1485
|
76.9 USD |
1 year ago
Mar 13, 2023
|
Sell 484 K USD
|
Parsey Merdad
Chief Medical Officer |
- 6126
|
78.99 USD |
1 year ago
Mar 01, 2023
|
Sell 1.04 M USD
|
Parsey Merdad
Chief Medical Officer |
- 12984
|
79.9619 USD |
1 year ago
Dec 30, 2022
|
Sell 47.2 K USD
|
Parsey Merdad
Chief Medical Officer |
- 553
|
85.33 USD |
2 years ago
Nov 09, 2022
|
Sell 536 K USD
|
Wilfong Diane E.
SVP, Controller & CAO |
- 6416
|
83.5 USD |
2 years ago
Nov 01, 2022
|
Sell 1.29 M USD
|
Wilfong Diane E.
SVP, Controller & CAO |
- 16255
|
79.25 USD |
2 years ago
Mar 10, 2022
|
Sell 212 K USD
|
Pletcher Brett A
EVP,Corp Affairs & Gen Counsel |
- 3634
|
58.24 USD |
2 years ago
Feb 09, 2022
|
Sell 108 K USD
|
Pletcher Brett A
EVP,Corp Affairs & Gen Counsel |
- 1691
|
63.89 USD |
2 years ago
Feb 01, 2022
|
Sell 964 K USD
|
Pletcher Brett A
EVP,Corp Affairs & Gen Counsel |
- 14061
|
68.5358 USD |
3 years ago
Aug 17, 2021
|
Sell 987 K USD
|
Wilfong Diane E.
SVP, Controller & CAO |
- 13610
|
72.5 USD |
3 years ago
May 04, 2021
|
Sell 1.29 M USD
|
Mercier Johanna
Chief Commercial Officer |
- 19496
|
66.0929 USD |
3 years ago
May 03, 2021
|
Sell 1.31 M USD
|
Whitley Richard James
Director |
- 20282
|
64.5723 USD |
3 years ago
Mar 11, 2021
|
Sell 94.2 K USD
|
Pletcher Brett A
EVP,Corp Affairs & Gen Counsel |
- 1486
|
63.36 USD |